

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

LUD 5298.5 DIV (10309270)

Dated: 2/25/04

Signature: Jani Malikouzakis (Jani Malikouzakis)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Issue Patent Application of: Kohei MIYAZONO et al.

Application No.: 10/630,555

Group Art Unit: 1623

Filed: July 30, 2003

Examiner: Not Yet Assigned

For: ANTIBODIES WHICH BIND SPECIFICALLY TO
ACTIVIN RECEPTOR LIKE KINASES

REQUEST FOR CORRECTED FILING RECEIPT

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has the following error:

In the Foreign Applications section, please change the sixth foreign application number to -- 9316099.2 --.

Please refer to the copy of the filing receipt, wherein the change is indicated. Applicants are also attaching a copy of the cover page of the international priority application wherein the correct foreign application number is listed.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. **LUD 5298.5 DIV (10309270)** from which the undersigned is authorized to draw.

Respectfully submitted,

By Norman D. Hanson

Norman D. Hanson

Registration No.: 30,946

FULBRIGHT & JAWORSKI L.L.P.

Attorney for Applicant

666 Fifth Avenue
New York, New York
(212) 318-3000
(212) 318-3400 (fax)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/630,555	07/30/2003	1623	750	NY-LUD 5298.5-DIV-US	11	2	1

CONFIRMATION NO. 7477

024972
 FULBRIGHT & JAWORSKI, LLP
 666 FIFTH AVE
 NEW YORK, NY 10103-3198

FILING RECEIPT



OC000000011486524

Date Mailed: 12/15/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kohei Miyazono, Uppsala, SWEDEN;
 Peter Ten Dijke, Uppsala, SWEDEN;
 Petra Franzen, Uppsala, SWEDEN;
 Hidetoshi Yamashita, Uppsala, SWEDEN;
 Carl-Henrik Heldin, Uppsala, SWEDEN;

Domestic Priority data as claimed by applicant

This application is a DIV of 09/903,068 07/11/2001
 which is a DIV of 09/679,187 10/03/2000 PAT 6,331,621
 which is a DIV of 08/436,265 10/30/1995 PAT 6,316,217
 which is a 371 of PCT/GB93/02367 11/17/1993

Foreign Applications

UNITED KINGDOM 9224057.1 11/17/1992
 UNITED KINGDOM 9304677.9 03/08/1993
 UNITED KINGDOM 9304680.3 03/08/1993
 UNITED KINGDOM 9311047.6 05/28/1993
 UNITED KINGDOM 9313763.6 07/02/1993
 UNITED KINGDOM 9136099.2 08/03/1993
 UNITED KINGDOM 9321344.5 10/15/1993

9313763.6 07/02/1993

If Required, Foreign Filing License Granted: 12/12/2003

Projected Publication Date: 03/25/2004

Non-Publication Request: No

Early Publication Request: No

Title

Antibodies which bind specifically to activin receptor like kinases

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/12, C07K 13/00 C12N 5/10, A61K 37/02 G01N 33/68		A2	(11) International Publication Number: WO 94/11502 (43) International Publication Date: 26 May 1994 (26.05.94)																																																		
<p>(21) International Application Number: PCT/GB93/02367</p> <p>(22) International Filing Date: 17 November 1993 (17.11.93)</p> <p>(30) Priority data:</p> <table> <tbody> <tr><td>9224057.1 ✓</td><td>17 November 1992 (17.11.92)</td><td>GB</td></tr> <tr><td>9304677.9 ✓</td><td>8 March 1993 (08.03.93)</td><td>GB</td></tr> <tr><td>9304680.3 ✓</td><td>8 March 1993 (08.03.93)</td><td>GB</td></tr> <tr><td>9311047.6 ✓</td><td>28 May 1993 (28.05.93)</td><td>GB</td></tr> <tr><td>9313763.6 ✓</td><td>2 July 1993 (02.07.93)</td><td>GB</td></tr> <tr><td>9316099.2</td><td>3 August 1993 (03.08.93)</td><td>GB</td></tr> <tr><td>9321344.5 ✓</td><td>15 October 1993 (15.10.93)</td><td>GB</td></tr> </tbody> </table> <p>(71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH (GB/GB); St. Mary's Hospital Medical School, Norfolk Place, Paddington, London W2 1PG (GB).</p>		9224057.1 ✓	17 November 1992 (17.11.92)	GB	9304677.9 ✓	8 March 1993 (08.03.93)	GB	9304680.3 ✓	8 March 1993 (08.03.93)	GB	9311047.6 ✓	28 May 1993 (28.05.93)	GB	9313763.6 ✓	2 July 1993 (02.07.93)	GB	9316099.2	3 August 1993 (03.08.93)	GB	9321344.5 ✓	15 October 1993 (15.10.93)	GB	<p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : MIYAZONO, Kohji [JP/SE]; Flogstavägen 63D, S-752 63 Uppsala (SE). DIJKE, Peter, Ten [NL/SE]; Flogstavägen 25C, S-752 63 Uppsala (SE). FRANZEN, Petra [SE/SE]; Lindsbergsgatan 15b, S-752 40 Uppsala (SE). YAMASHITA, Hidetoshi [JP/SE]; Flogstavägen 33A, S-752 63 Uppsala (SE). HELLDIN, Carl-Henrik [SE/SE]; Hesselmans väg 35, S-752 63 Uppsala (SE).</p> <p>(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p> <p>(81) Designated States: AU, CA, JP, KR, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>																														
9224057.1 ✓	17 November 1992 (17.11.92)	GB																																																			
9304677.9 ✓	8 March 1993 (08.03.93)	GB																																																			
9304680.3 ✓	8 March 1993 (08.03.93)	GB																																																			
9311047.6 ✓	28 May 1993 (28.05.93)	GB																																																			
9313763.6 ✓	2 July 1993 (02.07.93)	GB																																																			
9316099.2	3 August 1993 (03.08.93)	GB																																																			
9321344.5 ✓	15 October 1993 (15.10.93)	GB																																																			
<p>(54) Title: ACTIVIN RECEPTOR-LIKE KINASES, PROTEINS HAVING SERINE THREONINE KINASE DOMAINS AND THEIR USE</p> <p>cons.aa C-C-G-V A-X-E</p> <table> <tbody> <tr><td>MTGFR-II</td><td>LDTLVGTRFAEVYIQLKQNTSDQFETAVKIIFFPYDHYASWKRDKDIFPSDINLJHETILDF</td><td>I</td><td>II</td><td>III</td><td>IV</td></tr> <tr><td>BactR-IIIB</td><td>LLETIKARGRFCCVWIAQLMN-----DVAVKIKPLDKQSWOSEREI</td><td></td><td></td><td></td><td></td></tr> <tr><td>BactR-II</td><td>LLEVTKARGRFCCVWIAQLLN-----EVAVKIPPIQDKQSWQNZYEVYSI</td><td></td><td></td><td></td><td></td></tr> <tr><td>daf-1</td><td>LTGRVCSCRFGENVSKDGYRC-----EAVAVKVPAIDEAPAPKIEIEFETRMLRHMPAVLY</td><td></td><td></td><td></td><td></td></tr> <tr><td>subdomains</td><td></td><td></td><td></td><td></td><td></td></tr> </tbody> </table> <p>MTGFR-II LTAEERKTELKGQYMLITAFHAKGNLGEYLTRVVISWEDLRNVGSSLARGLSHLMSDHTPP-C</p> <p>BactR-IIIB IAAEIKGSNLEVEELIATAFHDKGSLIDYLKQNIITWNELCHVAETMSRGISYSLHEDVPWCR</p> <p>BactR-II IGAERKTSVDVDIKLITAFHEKGSLIDFLQARVSVWNECHIAETNARGLAYLHEDIPGLK</p> <p>daf-1 IGSDRVDTGTVTELGVIEYHPSGSLLHDFLLENVTVIETYYNLMRSTASCLAFLHNQIGSK</p> <p>subdomains V VI-A</p> <p>cons.aa DLX N DPG</p> <table> <tbody> <tr><td>MTGFR-II</td><td>-CRPKMPIVHRDLKSSNIVLVRNDLTCCLCDPGLSRL--CPYSSVDDLANSQVCTARYMAP</td><td>VII</td><td>VIII</td></tr> <tr><td>BactR-IIIB</td><td>CEGHUPPSIAKRDIFKSIQVLLKSDLTAVLAQFGLAVERF---EPGKPPGD--THGQVCTRRYMAP</td><td></td><td></td></tr> <tr><td>BactR-II</td><td>-DGKHPAIKSRDKTIVNLLQHNLTAICIAQFGLAJKF---BACKSAGD--THGQVCTRRYMAP</td><td></td><td></td></tr> <tr><td>daf-1</td><td>-ESNKPAKMRDIKSTKMYKRDLTCAQDOLQLSLSKPEDAASDIAN--ENYKCGTVRTYMAP</td><td></td><td></td></tr> <tr><td>subdomains</td><td>VI-B</td><td></td><td></td></tr> </tbody> </table> <p>(57) Abstract</p> <p>A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-β-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VI-B and/or a GTKRYM sequence in subdomain VIII.</p>				MTGFR-II	LDTLVGTRFAEVYIQLKQNTSDQFETAVKIIFFPYDHYASWKRDKDIFPSDINLJHETILDF	I	II	III	IV	BactR-IIIB	LLETIKARGRFCCVWIAQLMN-----DVAVKIKPLDKQSWOSEREI					BactR-II	LLEVTKARGRFCCVWIAQLLN-----EVAVKIPPIQDKQSWQNZYEVYSI					daf-1	LTGRVCSCRFGENVSKDGYRC-----EAVAVKVPAIDEAPAPKIEIEFETRMLRHMPAVLY					subdomains						MTGFR-II	-CRPKMPIVHRDLKSSNIVLVRNDLTCCLCDPGLSRL--CPYSSVDDLANSQVCTARYMAP	VII	VIII	BactR-IIIB	CEGHUPPSIAKRDIFKSIQVLLKSDLTAVLAQFGLAVERF---EPGKPPGD--THGQVCTRRYMAP			BactR-II	-DGKHPAIKSRDKTIVNLLQHNLTAICIAQFGLAJKF---BACKSAGD--THGQVCTRRYMAP			daf-1	-ESNKPAKMRDIKSTKMYKRDLTCAQDOLQLSLSKPEDAASDIAN--ENYKCGTVRTYMAP			subdomains	VI-B		
MTGFR-II	LDTLVGTRFAEVYIQLKQNTSDQFETAVKIIFFPYDHYASWKRDKDIFPSDINLJHETILDF	I	II	III	IV																																																
BactR-IIIB	LLETIKARGRFCCVWIAQLMN-----DVAVKIKPLDKQSWOSEREI																																																				
BactR-II	LLEVTKARGRFCCVWIAQLLN-----EVAVKIPPIQDKQSWQNZYEVYSI																																																				
daf-1	LTGRVCSCRFGENVSKDGYRC-----EAVAVKVPAIDEAPAPKIEIEFETRMLRHMPAVLY																																																				
subdomains																																																					
MTGFR-II	-CRPKMPIVHRDLKSSNIVLVRNDLTCCLCDPGLSRL--CPYSSVDDLANSQVCTARYMAP	VII	VIII																																																		
BactR-IIIB	CEGHUPPSIAKRDIFKSIQVLLKSDLTAVLAQFGLAVERF---EPGKPPGD--THGQVCTRRYMAP																																																				
BactR-II	-DGKHPAIKSRDKTIVNLLQHNLTAICIAQFGLAJKF---BACKSAGD--THGQVCTRRYMAP																																																				
daf-1	-ESNKPAKMRDIKSTKMYKRDLTCAQDOLQLSLSKPEDAASDIAN--ENYKCGTVRTYMAP																																																				
subdomains	VI-B																																																				